Endocan Expression and Relationship with Survival in Human Non–Small Cell Lung Cancer
Authors:
- Bogdan Dragos GrigoriuBGBogdan Dragos Grigoriu
- Florence DepontieuFDFlorence Depontieu
- Patrick DevosPDPatrick Devos
- Philippe LassallePLPhilippe Lassalle
- The Thoracic Oncology GroupTGThe Thoracic Oncology Group
- 1 August 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (15) , 4575-4582
Abstract
Purpose: We evaluated the expression of endocan, a soluble lung- and kidney-selective endothelial cell-specific dermatan sulfate proteoglycan, in non–small cell lung tumors compared with normal lung and studied the significance of high levels of circulating endocan in patients with non–small cell lung cancer. Material and Methods: Endocan and vascular endothelial growth factor mRNA expression were evaluated by semiquantitative PCR in tumoral and nontumoral lung tissue samples from a first series of 24 patients submitted to curative surgery. Relationships between survival, time to tumor progression, and serum levels of endocan were evaluated in a second series of 30 previously untreated patients addressed for staging. Results: In non–small cell lung cancers, endocan mRNA was overexpressed compared with control lung. Immunohistochemistry shows that endocan was expressed only by tumor endothelium in all cases, especially in the periphery of the tumors, with no differences between adenocarcinoma and squamous cell carcinoma. Endocan and vascular endothelial growth factor mRNA expression was positively correlated in lung tumors. Serum endocan levels, as well as tumor, node, and metastasis status, were correlated with both survival and time to tumor progression. However, endocan serum level was not an independent prognostic factor due to its correlation with the presence of metastasis. Conclusion: Endocan is overexpressed in non–small cell lung tumors compared with healthy lung and probably represents a response of tumoral endothelium to proangiogenic growth factor stimulation. Circulating levels of endocan might reflect tumor angiogenic stimulation and present prognostic significance.Keywords
This publication has 28 references indexed in Scilit:
- TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENTAnnual Review of Pathology: Mechanisms of Disease, 2006
- Endocan, a new endothelial marker in human sepsis*Critical Care Medicine, 2006
- Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinomaEuropean Journal of Cancer, 2005
- Tumour vascular targetingNature Reviews Cancer, 2005
- Angiogenesis and Lung Cancer: Prognostic and Therapeutic ImplicationsJournal of Clinical Oncology, 2005
- Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Characterization of the Secreted Form of Endothelial-Cell-Specific Molecule 1 by Specific Monoclonal AntibodiesJournal of Vascular Research, 2000
- The Hallmarks of CancerCell, 2000
- A human lymphocyte‐associated antigen involved in cell‐mediated lympholysisEuropean Journal of Immunology, 1983